Skip to Content

Join the 'Axumin' group to help and get support from people like you.

Axumin News

FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer

Posted 1 Jun 2016 by

May 27, 2016 – The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment. Prostate cancer is the second leading cause of death from cancer in U.S. ...

Ask a Question

Further Information

Related Condition Support Groups

Diagnosis and Investigation, Positron Emission Tomography Imaging

Axumin Patient Information at